captivate trial: 5.5yr follow-up of the fixed-duration cohort
Published 2 months ago • 64 plays • Length 1:34Download video MP4
Download video MP3
Similar videos
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:43
six-year update from cll14: fixed-duration venetoclax obinutuzumab for previously untreated cll
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll
-
0:47
overview of the phase iii enhance trial schema
-
9:15
how to update oneocean.from latest avcs/aio dvd onboard. #oneocean #update #navigator #navigation
-
3:16
how to use evarrest fibrin sealant patch for surgical bleeding management | ethicon
-
2:04
sutureloc™ implant for meniscal root repair
-
3:37
2 year dfs data from the captivate trial
-
0:54
a research update in richter's transformation from ash 2023
-
4:21
hovon 141/vision trial update: mrd-guided venetoclax ibrutinib treatment for r/r cll
-
1:22
shortening the duration of treatment with fixed-duration or mrd-adapted regimens in cll
-
0:44
the recent fda approval of ponatinib for ph all following success in the phallcon trial
-
1:50
novel treatment regimens under investigation for richter's transformation
-
1:01
update on the cll treatment landscape
-
1:39
retreatment with a btki plus venetoclax after relapse is effective in cll: insights from captivate
-
2:55
current and emerging treatments for mf: an update from ash 2023
-
1:30
the use of pirtobrutinib in richter's transformation: data from the bruin trial
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
2:19
how cutting-edge research is changing outcomes in myeloma and the need for novel endpoints in trials
-
1:26
improving outcomes in sickle cell disease: expanding access and expediting treatment development
-
1:09
the changing role of allosct in dlbcl in the era of novel agents